Johnson & Johnson (JNJ)
Healthcare · end-of-day data as of Oct 16, 2026
The average 12-month analyst price target for JNJ is $276.98, 8.4% above the last close of $255.56 on Oct 16, 2026; targets range from $215.83 to $319.13. Rating consensus: Buy.
Snapshot
- P/E38.7x
- P/E vs sector+37.6%
- P/E vs own+33.3%
- Target upside+8.8%
- ConsensusBuy
- Market cap$616B
- FCF yield—
- Insiders-$64.74M
- Earnings in96d
- News
Why it moved
Johnson & Johnson (JNJ) rose 0.9% on Oct 16, 2026.
The market (SPY) fell 1.1%; Healthcare stocks fell 0.8%. Most of the move is specific to JNJ.
5 stories on the day (30-day average 5.6).
- Johnson & Johnson $JNJ Position Boosted by Assenagon Asset Management S.A.
- The Stocks That Will Get Investors Home Safe When Tech Cracks
- Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
Market = SPY. Sector = equal-weight average of the tracked companies in the same sector, net of the market.
Price and events
Last close $255.56 · +36.0% over 1y · E earnings · D dividend · S split · A analyst rating change
Technicals
- Trendbullish
- Sector▲ +16.0%
- MAs20▼ 50▼ 100▲ 200▲
- Above MAs2 of 4 above
- MA20×50Death 5d ago
- RSI44
- Support-1.0%
- Resistance+4.9%
- Off 52w high-8.2%
- Off ATH-8.2%
- 52w range$255.56
- Bollingerlower half
- MACD-0.74
- ATR+2.4%
- Volume0.9x
Analyst price targets
17 firms with a target in the last 12 months · last close $255.56 · as of Oct 16, 2026
Strong buy 5 · Buy 11 · Hold 6 · Sell 1 · Strong sell 0
Revenue and free cash flow
Q3 FY2026: Revenue +5.9% year over year, operating margin 25.1%.
| Q3 FY2026 | Sep 30, 2026 | $25.4B | 0.09 | — | 73.0% | 25.1% | 0.8% |
| Q2 FY2026 | Jun 28, 2026 | $25.31B | 2.27 | $3.39B | 68.2% | 28.3% | 21.9% |
| Q1 FY2026 | Mar 29, 2026 | $24.06B | 2.14 | $1.47B | 66.3% | 26.6% | 21.8% |
| Q4 FY2025 | Dec 28, 2025 | $24.56B | 2.10 | $5.47B | 67.6% | 22.8% | 20.8% |
| Q3 FY2025 | Sep 28, 2025 | $23.99B | 2.12 | $8.38B | 69.6% | 29.6% | 21.5% |
| Q2 FY2025 | Jun 29, 2025 | $23.74B | 2.29 | $2.48B | 67.9% | 28.7% | 23.3% |
| Q1 FY2025 | Mar 30, 2025 | $21.89B | 4.54 | $3.38B | 66.4% | 28.8% | 50.2% |
| Q4 FY2024 | Dec 29, 2024 | $22.52B | 1.41 | $4.84B | 68.3% | 17.1% | 15.2% |
Peers
| 20D | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1 |  | $1,257.03 | +0.4% | -1.8% | +4.5% | 42.2 | $1.18T | |
| 2 | | $255.56 | +0.9% | -8.2% | +8.8% | 38.7 | $616B | |
| 3 |  | $285.42 | +0.7% | 0.0% | -1.4% | 80.4 | $504B | |
| 4 |  | $145.95 | +0.5% | -6.2% | +7.7% | 116.8 | $360B | |
| 5 |  | $432.49 | -0.4% | -2.6% | -7.5% | 26.9 | $234B | |
| 6 |  | $156.19 | -0.7% | -0.7% | +1.9% | — | $194B | |
| 7 |  | $29.58 | +0.5% | 0.0% | -7.1% | 39.1 | $169B | |
| 8 |  | $59.75 | -1.4% | -11.3% | +9.4% | 13.2 | $122B |
Data as of Oct 16, 2026 close.
Latest news
Sentiment classified by AI from the headline (green positive, red negative). Links open the publisher.